Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.4069
-0.0467 (-10.30%)
Nov 16, 2026, 4:00 PM EST - Market closed
Kairos Pharma Stock Forecast
KAPA's stock price has decreased by -92.99% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, Kairos Pharma stock has a consensus rating of "Buy" and an average price target of $49. The average 1-year stock price forecast is 11,942.27% higher than the current stock price, while the lowest is $14 (+3,340.65%) and the highest is $84 (+20,543.89%).
Price Target: $49 (+11,942.27%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Kairos Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Mar '26 | Apr '26 | May '26 | Jul '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +2,849.13% | Nov 6, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $14 | Buy | Maintains | $14 | +3,340.65% | Jul 23, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.59
from -2.10
EPS Next Year
-4.69
from -2.59
EPS and Forward PE are based on non-GAAP adjusted numbers.